Sarrat Anne, Brabant Séverine, Charbonnier Eric, Alyanakian Marie-Alexandra, Apoil Pol-André, Bienvenu Françoise, Jaby Délia, Lainé Catherine, Nicaise-Roland Pascale, Renier Gilles, Sainte-Laudy Jean, Tabary Thierry, Uring-Lambert Béatrice, Vigneron Céline, Lambert Claude
Laboratoire d'immunologie, CHU Bordeaux, Hôpital Pellegrin, Bordeaux, France.
Ann Biol Clin (Paris). 2013 May-Jun;71(3):325-32. doi: 10.1684/abc.2013.0830.
French medical laboratories must be accredited before November 2016 according to NF/EN/ISO 15189 standard. However, technical accreditation guidelines cannot be applied literally for the determination of specific IgE for several reasons: more than 600 allergen tests, lack of international gold standard, limited external quality controls. Furthermore, the technique for determination of specific IgE is CE DM-IVD marked, common to all specificities, automatised, standardized according to a single calibration curve. Thus, we propose an efficient but reasonable solution conform to the idea of the accreditation by validating the process. We recommend: a flexible extend type A; choice of only one representative allergen (Dermatophagoides pteronyssinus) for repeatability and precision (20 tests, 2 levels 0.5-1 and 8-12 kUA/L) performed on patients sera, reproducibility (30 consecutive determinations using an Internal Quality Control/IQC), accuracy (IQC and rare External Quality Controls) compared with peers. Sensitivity, specificity, dynamic range, detection threshold are determinated by the provider. Linearity may be checked if the laboratory practices sample dilution for values higher than the upper limit guaranteed by the provider. In the absence of international gold standard, the uncertainty is not measurable. In case of change of instrument, the results obtained by the systems must be compared through 35 tests of different specificities distributed across the range of calibration and including 5 values close to the detection limit. This methodology allows a scientifically effective verification, technically and financially reasonable, to ensure the excellence of the performance of the laboratory with regard to peers and users (allergologists and patients).
根据NF/EN/ISO 15189标准,法国医学实验室必须在2016年11月前获得认可。然而,由于多种原因,技术认可指南不能完全适用于特异性IgE的测定:超过600种过敏原检测、缺乏国际金标准、外部质量控制有限。此外,特异性IgE的测定技术具有CE DM-IVD标志,所有特异性通用,自动化,根据单一校准曲线标准化。因此,我们通过验证过程提出一种符合认可理念的高效但合理的解决方案。我们建议:采用灵活的扩展A型;仅选择一种代表性过敏原(屋尘螨)进行重复性和精密度验证(对患者血清进行20次检测,2个水平0.5-1和8-12 kUA/L)、再现性验证(使用内部质量控制/IQC进行30次连续测定)、与同行比较的准确性验证(IQC和罕见的外部质量控制)。灵敏度、特异性、动态范围、检测限由供应商确定。如果实验室对高于供应商保证上限的值进行样本稀释,则可检查线性。在没有国际金标准的情况下,不确定度无法测量。如果仪器发生变化,必须通过在校准范围内分布的35次不同特异性检测(包括5个接近检测限的值)比较各系统获得的结果。这种方法能够进行科学有效的验证,在技术和财务上合理,以确保实验室相对于同行和用户(过敏症专科医生和患者)的卓越性能。